MOSCOW, Apr 27 (PRIME) -- Russian pharmaceutical company Nanolek plans to invest 5 billion rubles in creation of its own full-cycle production of vaccines in the next three years, the company said in a statement on Tuesday.
“Nanolek announces its plan to invest 5 billion rubles in the next three years in its own full-cycle production of vaccines at a plant in the Kirov Region and a R&D center of biotechnology medicines in Moscow. Tripling the current vaccine portfolio is necessary until 2025,” the statement read.
Currently, the company’s vaccines account for 20% of Russia’s state procurements of vaccines for the national prophylaxis vaccine calendar, and the company wants to raise the share significantly.
“Our plan is to have four or five medicines developed by us in our portfolio in several years. It is the only way to become the leader of the Russian vaccine market and enter the international markets,” President Vladimir Khristenko said as quoted by the company.
(74.7680 rubles – U.S. $1)
End %%md%/jst%
|
|
